Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 255Breast Neoplasms 172Neoplasms 167Colorectal Neoplasms 154Neoplasm Metastasis 127Melanoma 119Recurrence 116Prostatic Neoplasms 116Leukemia, Myeloid, Acute 115Pancreatic Neoplasms 113Ovarian Neoplasms 110Multiple Myeloma 103Lung Neoplasms 95Stomach Neoplasms 89Squamous Cell Carcinoma of Head and Neck 82Triple Negative Breast Neoplasms 81Glioblastoma 81Lymphoma 76Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 64Carcinoma, Renal Cell 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 57Small Cell Lung Carcinoma 54Sarcoma 52Uterine Cervical Neoplasms 51Myelodysplastic Syndromes 51Advanced Solid Tumors 49

Interventions

pembrolizumab 2poly(I).poly(c12,U) 1liposomal doxorubicin 1Paclitaxel 1Gemcitabine 1Cisplatin 1Carboplatin 1Bevacizumab 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Ovarian Cancer Recurrent × 1 year × Clear all
NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
460 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

University of Pittsburgh

Phase 1/2 Active not recruiting
24 enrolled 59 charts
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡